MedTrace Logo

Dornase Alfa and Urokinase for Kids With Pleural Empyema

NCT00502632 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2008-05-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether intrapleural treatment with Dornase alfa plus Urokinase improves clinical outcome compared to Urokinase alone in children with complicated parapneumonic effusions

Conditions

  • Pleural Empyema

Interventions

DRUG

Urokinase and Dornase alfa

Intrapleural administration of: * Urokinase 40,000 in 40ml normal saline, twice daily for 4 days * Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days

DRUG

Urokinase

Intrapleural administration of: * Urokinase 40,000 in 40ml normal saline, twice daily for 4 days * 25ml normal saline, twice daily for 4 days

Sponsors & Collaborators

Principal Investigators

  • PierGiorgio Gamba, MD · Azienda Ospedaliera di Padova

  • Giorgio Stefanutti, MD · Women's and Children's Hospital, Adelaide, SA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Completion
2009-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00502632 on ClinicalTrials.gov